Clicky

Friday, January 15th, 2021

Emergent BioSolutions invests $75M in viral vector, gene therapy capabilities

© Shutterstock

Emergent BioSolutions revealed this week plans to expand its viral vector and gene therapy capabilities.

The company announced it will invest $75 million in its Canton, Mass., facility, which is focused on the contract development and manufacturing (CDMO) of drug substances for live viral vaccines, including the company’s smallpox vaccine

“Emergent’s expansion into advanced therapy CDMO services is based on our biologics expertise and a strong understanding of our customers’ current and future needs,” said Sean Kirk, executive vice president of manufacturing and technical operations at Emergent BioSolutions. “We are investing in our people, plants, and products to meet the growing demand for precision treatments and to help get these therapies to patients.”

The investment will include a state-of-the-art, multi-suite operation up to 1000L scale. The company plans to provide full molecule-to-market CDMO services for viral vector and gene therapy innovators, by offering development services out of its Gaithersburg, Md., location, drug substance manufacturing out of Canton, and drug product manufacturing at its Rockville location, which is undergoing an expansion scheduled to be operational at the end of 2021.

“We are energized by the continued growth of our CDMO offerings and this new focus on advanced therapies,” Syed Husain, senior vice president and CDMO business unit head, said. “As a leading CDMO service provider, our goal is to support the needs of industry and fellow innovators in line with our mission – to protect and enhance life.”

Emergent’s CDMO business has the capability to work with five technology platforms – mammalian, microbial, live viral, advanced therapy, and plasma – across a network of nine development and manufacturing sites. This allows it to support the entire drug development life cycle.

The addition of advanced therapy scale to the Canton facility will build upon its biologics platforms and will complement existing capabilities related to the company’s smallpox vaccine. Through this expansion, Emergent further secures the long-term supply chain of the only single-dose smallpox vaccine and broadens its advanced therapy capabilities increasing its overall CDMO service offerings.